# Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

> **NCT01641393** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 96 (actual)

## Conditions studied

- Exocrine Pancreatic Insufficiency: Cystic Fibrosis

## Interventions

- **DRUG:** EUR-1008 25,000 Units
- **DRUG:** Kreon 25,000 Units

## Key facts

- **NCT ID:** NCT01641393
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2014-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641393, "Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01641393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*